Rx Medicare

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced preliminary results from a Phase 1 study assessing two new formulations of the opioid analgesic buprenorphine utilizing the company’s proprietary BEMA? drug delivery technology. The study was performed to select the optimal formulation for Phase 2 clinical development of the product candidate, known as BEMA? Buprenorphine.

Read More…

Related Posts

• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• Alkermes Announces Positive Results For Phase 1 Study Of New Drug Candidate For Treatment Of Opioid-Induced Constipation
• Phosphagenics Announces Positive Results From Phase 1B Study Of Transdermal Oxycodone Patch
• SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus In Initial Pilot Animal Study
• AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
• Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study For The Treatment Of Postherpetic Neuralgia (PHN)
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• Labopharm Reports Results For Phase III Study On Twice-daily Tramadol-acetaminophen Formulation
• Nektar Announces Positive Results From Phase 2 Study Of Oral NKTR-118 In Patients With Opioid-Induced Constipation (OIC)
• SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
• QRxPharma Initiates Second Pivotal Phase 3 Study Of MoxDuo(TM)IR Dual-Opioid(TM) For NDA Submission
• SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza

Tags: bema, buprenorphine, favorable, following, initial, phase, proceed, results, study

This entry was posted on Friday, March 20th, 2009 at 1:03 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.